Parenchymal-sparing Hepatectomy as the New Doctrine in the Treatment of Liver-metastatic Colorectal Disease: Beyond Oncological Outcomes.

Abstract

Colorectal cancer is one of the leading causes of mortality in the Western world. Half of patients with colorectal cancer will develop liver-metastatic (CLM) disease, with fewer than 30% having surgically resectable disease at diagnosis. It is well established in the literature that major hepatectomy offers a high rate of R0 resection, however, with concommitant increased rates of mortality and morbidity. Emerging literature during the past two decades has demonstrated the potential superiority of parenchymal-sparing hepatectomy (PSH) in treating CLM disease in terms of oncological outcomes, survival and re-operation in cases of recurrence (salvageability). To date, no data regarding the evaluation of quality of life and cost after PSH have been published. PSH seems to be correlated with less mortality and morbidity, which can be translated in lower re-admission rates, better quality of life and, therefore, reduced relevant cost. Prospective studies and clinical trials evaluating the multiple beneficial role of a PSH surgical strategy in CLM disease are mandatory to support or reject the emerging belief that PSH could be the gold standard of treatment of CLM disease.

1 Figure or Table

Statistics

02004002017
Citations per Year

124 Citations

Semantic Scholar estimates that this publication has 124 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Moris2017ParenchymalsparingHA, title={Parenchymal-sparing Hepatectomy as the New Doctrine in the Treatment of Liver-metastatic Colorectal Disease: Beyond Oncological Outcomes.}, author={Demetrios Moris and Dimitrios Dimitroulis and Spyridon Vernadakis and Alexandros Papalampros and Eleftherios Spartalis and Athanasios S Petrou and Timothy M Pawlik and Evangelos Felekouras}, journal={Anticancer research}, year={2017}, volume={37 1}, pages={9-14} }